TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Nordic Biolabs AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
10,875
|
10,045
|
10,331 |
| Financial expenses |
11
|
16
|
4 |
| Earnings before taxes |
90
|
-259
|
-130 |
| EBITDA |
198
|
-131
|
3 |
| Total assets |
3,018
|
3,491
|
3,171 |
| Current assets |
2,809
|
3,259
|
2,833 |
| Current liabilities |
1,717
|
2,312
|
2,092 |
| Equity capital |
1,202
|
1,173
|
1,015 |
| - share capital |
209
|
216
|
216 |
| Employees (average) |
29
|
30
|
28 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
39.8%
|
33.6%
|
32.0% |
| Turnover per employee |
375
|
335
|
369 |
| Profit as a percentage of turnover |
0.8%
|
-2.6%
|
-1.3% |
| Return on assets (ROA) |
3.3%
|
-7.0%
|
-4.0% |
| Current ratio |
163.6%
|
141.0%
|
135.4% |
| Return on equity (ROE) |
7.5%
|
-22.1%
|
-12.8% |
| Change turnover |
1,172
|
-317
|
-261 |
| Change turnover % |
12%
|
-3%
|
-2% |
| Chg. No. of employees |
-1
|
2
|
3 |
| Chg. No. of employees % |
-3%
|
7%
|
12% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.